Vibegron effective in long-term treatment of overactive bladder

Reuters Health - 27/01/2021 - Vibegron is safe and shows lasting efficacy in treatment of overactive bladder (OAB), according to a company-funded extension trial of an earlier successful 12-week study. Vibegron, marketed as Gemtesa by Urovant Sciences, was approved for treating OAB by the U.S. Food and Drug Administration (FDA) in December 2020. "There is a large unmet need for medications for patients with bladder symptoms of urinary urgency, frequency, and incontinence," lead author Dr. David Staskin of St. Elizabeth Medical Center/Steward Health, in Boston, told Reuters Health by email. "In addition to the sustained efficacy, (vibegron) was well tolerated," he added. "The recent FDA approval based on the findings of this study will provide an important addition to treatment options which will benefit patients." In the original phase-3 study, funded by Urovant Sciences, more than 1,500 patients received once-daily vibegron 75 mg or tolterodine 4 mg o...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 27 January, 20218 February, 2021